FGP
CAPR icon

Freestone Grove Partners’s Capricor Therapeutics CAPR Stock Holding History

Freestone Grove Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,920
Closed -$316K – 605
2024
Q4 		$316K Buy
+22,920
New +$402K ﹤0.01% 457

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Freestone Grove Partners's CAPR Position: Q1 2025 in Review

Freestone Grove Partners sold out of Capricor Therapeutics (CAPR) in Q1 2025, closing a stake of 22,920 shares — an estimated $316K sold.

Freestone Grove Partners first reported a position in CAPR in Q4 2024 and held it in 1 quarter. The position peaked at $316K in Q4 2024. 120 funds tracked by Wall St. Rank hold CAPR as of Q1 2025.

  • Freestone Grove Partners reported no remaining Capricor Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 22,920 Capricor Therapeutics shares in Q1 2025, an estimated $316K.
  • Freestone Grove Partners first reported a position in Capricor Therapeutics in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Capricor Therapeutics position peaked at $316K in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.